Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
30 September 2024
Corporate presentations

CORPORATE PRESENTATION – SEPTEMBER 2024 Open in new window

26 September 2024
Financial statements and reports

2024 HALF-YEAR FINANCIAL REPORT Open in new window

23 September 2024
Regulated information

CONVERTIBLE BONDS ISSUED ON DECEMBER 28, 2022 Open in new window

17 July 2024
Regulated information

CONVERTIBLE BONDS ISSUED ON DECEMBER 28, 2022 Open in new window

12 July 2024
Regulated information

Monthly Information regarding the total number of voting rights Open in new window

11 July 2024
Investor newsletter

Investor Newsletter – July 2024 (French) Open in new window

30 May 2024
General meetings, Regulated information

2024 AGM Open in new window

30 May 2024
Regulated information

quorum Open in new window

29 May 2024
General Assembly, General meetings

Compensation policy of the Chief Executive Officer and/or any other corporate officer Open in new window

23 May 2024
Regulated information

Monthly Information regarding the total number of voting rights Open in new window

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 23
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page